Previous trial results had shown that the drug did not help patients with less severe COVID-19, the disease caused by the novel coronavirus, and shares of Regeneron fell about 3% in after hours trading. Other drugs in the same class, including Roche Holding AG’s Actemra, are also being studied as treatments for COVID-19. Patients who required mechanical ventilation or high-flow oxygen therapy or treatment in an intensive care unit were considered critically ill. …read more
Source:: Yahoo Finance
